SR18662 significantly reduces growth and proliferation of CRC cells and shows improved efficacy in reducing viability of multiple CRC cell lines. Flow cytometry analysis following SR18662 treatment shows an increase in cells captured in either S or G2/M phases of the cell cycle and a significant increase in the number of apoptotic cells. SR18662 also reduces the expression of cyclins and components of WNT and MAPK signaling pathways.[1]

The effect of SR18662 treatment shows a significant dose-dependent inhibition of xenograft growth in mice and exceeds ML264 at equivalent doses. SR18662 is potential for colorectal cancer therapy.[1]